FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063670594> ?p ?o ?g. }

• W2063670594 endingPage "028" @default.
• W2063670594 startingPage "015" @default.
• W2063670594 abstract "Imexon is an aziridine-containing small molecule currently in Phase I clinical trials. This agent has been shown to bind to thiols and increase intracellular oxidants, inducing apoptosis in hematologic cancer cells. Pancreatic cancers are known to be sensitive to oxidation, suggesting this disease may be an appropriate target for this agent. The current report examines the activity of imexon in pancreatic cells. Imexon induced concentration-dependent and time-dependent apoptosis in a panel of six human pancreatic carcinoma cell (PCC) lines. The mean IC50 (SD) for growth inhibition by the SRB assay was 200 (101) microM for a 48 h exposure with a range of 64-358 microM. Cell killing was schedule-dependent, favoring exposure times > or =48 h. Imexon-treated MiaPaCa-2 cells underwent non-lethal growth arrest following exposure to concentrations < or =200 microM for 48 h. When concentrations were increased to 300 microM for > or =48 h, the MiaPaCa-2 cells arrested in G2 phase and activated caspases 3, 8, and 9 were detected. After a 72 h exposure to the IC80 concentration of imexon, cells exhibited a loss of mitochondrial membrane potential detected by CMXRos staining. However, there was no loss of reduced cellular thiols unless very high concentrations of > or =400 microM were used. In contrast, reactive oxygen species (ROS) were elevated in a dose-dependent fashion, starting at very low imexon concentrations. Imexon also significantly inhibited MiaPaCa-2 tumor growth in SCID mice at 100 mg/kg/d for 9 d. The tumor growth inhibition (% T/C) was 27% of control, and the tumor growth delay was 21 d, indicating an active agent by NCI standards. The levels of imexon that are cytotoxic in human PCC's are achievable based on the preliminary results of the ongoing Phase I trial. Imexon appears to be active against PCCs in vitro and has an entirely novel mechanism of action involving G2 arrest, accumulation of ROS, and the induction of apoptosis." @default.
• W2063670594 created "2016-06-24" @default.
• W2063670594 creator A5000282495 @default.
• W2063670594 creator A5004500249 @default.
• W2063670594 creator A5031908913 @default.
• W2063670594 creator A5070130751 @default.
• W2063670594 creator A5073589476 @default.
• W2063670594 date "2005-01-01" @default.
• W2063670594 modified "2023-09-27" @default.
• W2063670594 title "Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines" @default.
• W2063670594 cites W145580528 @default.
• W2063670594 cites W1543918342 @default.
• W2063670594 cites W1547863599 @default.
• W2063670594 cites W1562677986 @default.
• W2063670594 cites W1907962006 @default.
• W2063670594 cites W1931508686 @default.
• W2063670594 cites W1975453622 @default.
• W2063670594 cites W1976666971 @default.
• W2063670594 cites W1977264994 @default.
• W2063670594 cites W1982756904 @default.
• W2063670594 cites W1988353980 @default.
• W2063670594 cites W1989539701 @default.
• W2063670594 cites W2008714118 @default.
• W2063670594 cites W2009046954 @default.
• W2063670594 cites W2015112307 @default.
• W2063670594 cites W2053928409 @default.
• W2063670594 cites W2054870962 @default.
• W2063670594 cites W2055867905 @default.
• W2063670594 cites W2064707851 @default.
• W2063670594 cites W2064777323 @default.
• W2063670594 cites W2072569792 @default.
• W2063670594 cites W2073336864 @default.
• W2063670594 cites W2081027426 @default.
• W2063670594 cites W2085897581 @default.
• W2063670594 cites W2088054041 @default.
• W2063670594 cites W2090795456 @default.
• W2063670594 cites W2092040852 @default.
• W2063670594 cites W2109689528 @default.
• W2063670594 cites W2109694492 @default.
• W2063670594 cites W2121120744 @default.
• W2063670594 cites W2121296375 @default.
• W2063670594 cites W2123627500 @default.
• W2063670594 cites W2125244026 @default.
• W2063670594 cites W2132235170 @default.
• W2063670594 cites W2138302361 @default.
• W2063670594 cites W2141365582 @default.
• W2063670594 cites W2153677362 @default.
• W2063670594 cites W2159013865 @default.
• W2063670594 cites W2162651519 @default.
• W2063670594 cites W2169790726 @default.
• W2063670594 cites W2188751783 @default.
• W2063670594 cites W2260154196 @default.
• W2063670594 cites W2300075112 @default.
• W2063670594 cites W2316210347 @default.
• W2063670594 doi "https://doi.org/10.1385/ijgc:36:1:015" @default.
• W2063670594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16227632" @default.
• W2063670594 hasPublicationYear "2005" @default.
• W2063670594 type Work @default.
• W2063670594 sameAs 2063670594 @default.
• W2063670594 citedByCount "23" @default.
• W2063670594 countsByYear W20636705942012 @default.
• W2063670594 countsByYear W20636705942014 @default.
• W2063670594 countsByYear W20636705942016 @default.
• W2063670594 countsByYear W20636705942018 @default.
• W2063670594 countsByYear W20636705942021 @default.
• W2063670594 countsByYear W20636705942022 @default.
• W2063670594 countsByYear W20636705942023 @default.
• W2063670594 crossrefType "journal-article" @default.
• W2063670594 hasAuthorship W2063670594A5000282495 @default.
• W2063670594 hasAuthorship W2063670594A5004500249 @default.
• W2063670594 hasAuthorship W2063670594A5031908913 @default.
• W2063670594 hasAuthorship W2063670594A5070130751 @default.
• W2063670594 hasAuthorship W2063670594A5073589476 @default.
• W2063670594 hasConcept C121608353 @default.
• W2063670594 hasConcept C126322002 @default.
• W2063670594 hasConcept C185592680 @default.
• W2063670594 hasConcept C190283241 @default.
• W2063670594 hasConcept C2780210213 @default.
• W2063670594 hasConcept C48349386 @default.
• W2063670594 hasConcept C502942594 @default.
• W2063670594 hasConcept C54355233 @default.
• W2063670594 hasConcept C55493867 @default.
• W2063670594 hasConcept C62112901 @default.
• W2063670594 hasConcept C71924100 @default.
• W2063670594 hasConcept C79879829 @default.
• W2063670594 hasConcept C81885089 @default.
• W2063670594 hasConcept C86803240 @default.
• W2063670594 hasConcept C98274493 @default.
• W2063670594 hasConceptScore W2063670594C121608353 @default.
• W2063670594 hasConceptScore W2063670594C126322002 @default.
• W2063670594 hasConceptScore W2063670594C185592680 @default.
• W2063670594 hasConceptScore W2063670594C190283241 @default.
• W2063670594 hasConceptScore W2063670594C2780210213 @default.
• W2063670594 hasConceptScore W2063670594C48349386 @default.
• W2063670594 hasConceptScore W2063670594C502942594 @default.
• W2063670594 hasConceptScore W2063670594C54355233 @default.
• W2063670594 hasConceptScore W2063670594C55493867 @default.
• W2063670594 hasConceptScore W2063670594C62112901 @default.

• next